NCT07265947Phase 2Recruiting

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Study sponsor: Tyra Biosciences, Inc · TYRA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-10Estimated
Enrollment · participants285Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 55 participants

Before: 230 participants (planned). After: 285 participants (planned).

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source